Tag: lurbinectedin
No posts to display
News
Candel Therapeutics receives FDA Orphan Drug Designation for pancreatic cancer treatment
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-2409, Candel Therapeutics' most advanced multimodal biological immunotherapy candidate, for the...
Rallybio collaborates with Johnson & Johnson to advance therapies for fetal and neonatal alloimmune...
Rallybio has announced a collaboration with Johnson & Johnson to support the development of complementary therapeutic approaches aimed at reducing the risk of fetal...
Lisata Therapeutics gains U.S. FDA Orphan Drug Designation for osteosarcoma treatment
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LSTA1, Lisata Therapeutics’ lead product candidate for the treatment of...
